MSO Mergers & Acquisitions: Consolidation Trends in Cannabis Markets

Executive Summary

Multi-state operator (MSO) mergers and acquisitions have reshaped the U.S. cannabis industry since 2018, with transaction values exceeding $15 billion as companies pursue vertical integration, geographic expansion, and operational scale. The sector's consolidation accelerated following state-level legalization waves, with major deals including Curaleaf's $875 million acquisition of Grassroots in 2020, Cresco Labs' $820 million purchase of Columbia Care in 2023, and most recently Vireo Growth's July 2026 acquisition of The Cannabist Company assets across five states. These transactions reflect an industry maturing under federal prohibition constraints, where MSOs cannot access traditional capital markets or cross state lines with product, forcing growth through asset purchases rather than organic expansion. The M&A landscape is defined by all-stock transactions to preserve cash, earnout structures to bridge valuation gaps, and complex regulatory approval processes requiring state-by-state licensing transfers. With 38 states now permitting medical or adult-use cannabis and federal rescheduling under consideration, the next wave of consolidation will determine which operators achieve the scale necessary to compete in an eventual national market.

Why MSO Mergers Matter

Cannabis M&A transactions directly impact 428,000 industry employees, 15,200 licensed dispensaries, and $33.6 billion in annual legal sales across state-regulated markets. For patients and consumers, consolidation affects product availability, pricing, and retail access as regional operators are absorbed into national chains. Medical cannabis patients in limited-license states like New York, Ohio, and Pennsylvania depend on MSO-operated dispensaries for consistent access to standardized products, making ownership changes material to treatment continuity. For investors, MSO M&A represents the primary liquidity mechanism in an industry excluded from Nasdaq and NYSE listing requirements. Canadian Securities Exchange and over-the-counter markets host U.S. cannabis operators, with transaction announcements routinely moving share prices 20-40% as shareholders evaluate strategic fit and synergy potential. The sector's institutional investor base—including ETFs like AdvisorShares Pure US Cannabis (MSOS) managing $340 million—relies on M&A activity to drive portfolio returns absent federal legalization catalysts. State governments face revenue implications as consolidation concentrates market share. Illinois collected $445 million in cannabis taxes in 2025, with the top four MSOs controlling 62% of retail sales. Merger approvals require state regulators to balance competitive concerns against the reality that undercapitalized operators may exit markets entirely without acquisition pathways. Social equity applicants, awarded licenses in 19 states to remediate drug war harms, increasingly partner with or sell to MSOs for capital access, creating tension between equity goals and consolidation pressures.

Background and History

Early Medical Era (1996-2013)

The modern cannabis M&A market traces to California's Proposition 215 passage in 1996, though transactions remained local and informal under federal prohibition. Early medical programs in California, Colorado, and Oregon operated as nonprofit collectives or caregiver models, with no legal mechanism for interstate commerce or corporate ownership transfers. The industry's first recognizable acquisition occurred in 2009 when Harborside Health Center in Oakland purchased a competing dispensary's patient list and inventory for an undisclosed sum, establishing a template for asset-based deals that avoided corporate stock transfers. Colorado's 2010 implementation of comprehensive medical regulations under House Bill 1284 created the industry's first vertically integrated license structure, requiring dispensaries to grow 70% of their inventory. This "seed-to-sale" mandate forced consolidation as undercapitalized retailers sold to operators with cultivation capacity. Denver-based Medicine Man Technologies completed 14 acquisitions between 2010-2013, assembling Colorado's first multi-location chain and pioneering the MSO model that would dominate the next decade.

Adult-Use Legalization and MSO Formation (2014-2017)

Washington and Colorado's adult-use market launches in 2014 triggered the first wave of institutional capital and multi-state expansion strategies. Privateer Holdings raised $82 million in venture funding in 2014 to acquire Leafly and Tilray, while Brendan Kennedy's Tilray pursued a Canadian public listing strategy that would later enable U.S. acquisitions. The industry's corporate structure bifurcated: Canadian licensed producers pursued TSX and NYSE listings under the Cannabis Act, while U.S. operators remained private or listed on the Canadian Securities Exchange to avoid federal enforcement under the Controlled Substances Act. The 2015-2016 period saw formation of the MSOs that would dominate subsequent M&A activity. Curaleaf launched in 2015 through a reverse takeover of Lead Ventures, acquiring licenses in Massachusetts, New Jersey, and Florida. Green Thumb Industries consolidated Illinois operations and expanded to Nevada and Pennsylvania. Cresco Labs assembled a vertically integrated Illinois platform and entered Ohio and Pennsylvania through competitive license applications. These operators raised private equity at $200-400 million valuations, using capital to acquire licenses in limited-license states where application processes favored well-capitalized entrants. The industry's first nine-figure transaction closed in August 2018 when Harvest Health & Recreation agreed to acquire Verano Holdings for $850 million in stock, a deal ultimately restructured after regulatory delays. GTI acquired Rise dispensaries in Illinois and Nevada for $68 million in cash and stock in November 2018, establishing the all-stock transaction structure that would become industry standard as operators preserved cash for license applications and buildouts.

Consolidation Acceleration (2018-2020)

The 2018-2020 period produced $8.2 billion in announced cannabis M&A transactions as MSOs pursued national footprints ahead of anticipated federal reform. Curaleaf's July 2020 acquisition of Grassroots for $875 million in stock created the industry's largest operator by revenue, adding cultivation and retail in Illinois, Michigan, and Pennsylvania. The transaction required approval from 11 state regulators and took 14 months to close, illustrating the complexity of multi-state deals under federalism constraints. Cresco Labs and Columbia Care announced an $820 million merger in March 2022, combining the industry's second and sixth-largest operators. The deal faced extended regulatory review in New York and Massachusetts, where combined market share exceeded 20%, ultimately closing in January 2023 after 10 months of state approvals and license divestitures. Trulieve acquired Harvest Health for $2.1 billion in all-stock consideration in October 2021, creating a 149-dispensary operator concentrated in Florida and Arizona. This consolidation wave coincided with capital markets exuberance. The AdvisorShares Pure US Cannabis ETF launched in April 2020, reaching $1.8 billion in assets by February 2021 as retail investors anticipated federal legalization under unified Democratic government. MSO valuations reached 8-12x forward revenue multiples, enabling stock-based acquisitions at prices that would prove unsustainable. Curaleaf's market capitalization peaked at $14.6 billion in February 2021; by December 2023 it had declined to $2.8 billion as federal reform stalled and operators missed growth projections.

Market Correction and Strategic Consolidation (2021-2024)

Cannabis M&A transaction volume declined 64% from 2021 to 2023 as rising interest rates, federal reform delays, and oversupply conditions compressed valuations. Announced deal value fell from $4.1 billion in 2021 to $1.5 billion in 2023, according to Viridian Capital Advisors tracking. The correction forced operators to prioritize profitability over growth, with major MSOs reducing acquisition activity to focus on operational efficiency and debt reduction. The period produced notable distressed transactions. MedMen, once valued at $3 billion, sold its Arizona and Florida licenses to Verano and Ayr Wellness in separate 2022 transactions for combined consideration under $100 million. Acreage Holdings, which had agreed to a $3.4 billion acquisition by Canopy Growth contingent on federal legalization, restructured the deal in 2023 to a $37 million asset sale after legalization failed to materialize. iAnthus Capital filed for creditor protection in 2020, with assets ultimately acquired by senior lenders in a debt-for-equity conversion. State regulatory scrutiny intensified as consolidation concentrated market power. Massachusetts Cannabis Control Commission imposed a 2022 moratorium on large operator license transfers pending market structure review. New York's Office of Cannabis Management required Cresco Labs to divest four dispensary licenses as a condition of the Columbia Care merger approval, establishing precedent for competitive review in limited-license markets.

Current Environment (2025-2026)

The July 2026 Vireo Growth acquisition of The Cannabist Company assets signals renewed M&A activity as operators pursue vertical integration and distressed asset opportunities. Transaction volume increased 28% in the first half of 2026 compared to the prior-year period, driven by three factors: federal rescheduling momentum following DEA's April 2024 notice of proposed rulemaking to move cannabis from Schedule I to Schedule III under 21 U.S.C. § 812; state market maturation creating acquisition targets among undercapitalized operators; and improved capital access as MSOs achieved EBITDA profitability and reduced debt burdens. The current M&A landscape favors strategic tuck-in acquisitions over transformative mergers. Operators target specific state licenses to achieve vertical integration, add cultivation capacity in supply-constrained markets, or acquire retail locations in high-traffic corridors. Asset purchases dominate over stock mergers as buyers preserve equity value and avoid dilution at depressed valuations. Earnout structures bridge valuation gaps, with 40-60% of consideration contingent on revenue or EBITDA targets over 12-24 month periods.

Key Players in Cannabis M&A

Major Multi-State Operators

Curaleaf Holdings operates 151 dispensaries across 18 states and generated $1.38 billion in 2025 revenue, making it the industry's largest operator and most active acquirer. The company completed 62 acquisitions since 2015, including the transformative Grassroots and Select transactions. Curaleaf's strategy prioritizes limited-license states where vertical integration creates competitive moats, with concentrated positions in New Jersey, Pennsylvania, and Florida. The company maintains a $150 million acquisition facility for opportunistic purchases. Green Thumb Industries operates 93 retail locations across 15 states under the Rise and Cookies brands, generating $1.04 billion in 2025 revenue. GTI pursues organic growth over M&A, having completed only 12 acquisitions since 2018, focusing capital on new market entries through competitive license applications. The company's selective acquisition approach targets retail locations in existing markets to densify geographic coverage and leverage existing wholesale distribution. Trulieve Cannabis operates 194 dispensaries concentrated in Florida, where it holds 51% adult-use market share, and generated $1.29 billion in 2025 revenue. The company's 2021 Harvest Health acquisition established positions in Arizona and Pennsylvania, though subsequent integration challenges and goodwill impairments reduced acquisition appetite. Trulieve focuses on Florida market dominance and selective expansion in limited-license states. Cresco Labs operates 58 dispensaries across 10 states following its 2023 Columbia Care merger, generating $822 million in 2025 revenue. The company's wholesale distribution business supplies 1,800 third-party retailers, creating acquisition synergies through retail channel access. Cresco targets vertically integrated acquisitions in wholesale-distribution markets including California, Massachusetts, and Illinois.

Private Equity and Investment Firms

Poseidon Investment Management manages $250 million across two cannabis-focused funds and pioneered institutional private equity investment in the sector starting in 2014. The firm's portfolio includes equity stakes in 14 MSOs and provides acquisition financing through senior secured debt facilities. Poseidon's investment thesis centers on consolidation creating national operators capable of competing in a post-legalization market, with realized returns dependent on eventual M&A exits or public market liquidity. Gotham Green Partners operates $1.1 billion in cannabis-focused credit and equity funds, providing acquisition financing to MSOs through senior secured term loans at 12-15% interest rates. The firm's credit facilities include change-of-control provisions requiring consent for M&A transactions, giving Gotham effective veto rights over major deals. This lender influence shapes transaction structures and valuation negotiations. Merida Capital Partners manages $175 million focused on cannabis technology and ancillary services, avoiding plant-touching operations to maintain federal compliance. The firm's portfolio companies including compliance software and extraction equipment manufacturers benefit from MSO consolidation as larger operators standardize technology platforms. Merida represents the parallel M&A market in cannabis services and technology.

Investment Banks and Advisors

Viridian Capital Advisors has advised on $12 billion in cannabis M&A transactions since 2015, including the Curaleaf-Grassroots and Cresco-Columbia Care mergers. The firm publishes quarterly M&A market reports tracking transaction volume, valuation multiples, and deal structures. Viridian's advisory practice focuses on sell-side mandates for mid-sized operators seeking liquidity through strategic sales. Canaccord Genuity maintains the industry's largest cannabis investment banking practice, with 18 dedicated bankers advising on equity raises and M&A transactions. The firm's capital markets platform provides acquirers access to institutional investors for financing, while its advisory practice represents both buyers and sellers in negotiated transactions. Canaccord advised on 34 cannabis M&A deals totaling $2.1 billion in transaction value from 2023-2025.

State Regulatory Agencies

State cannabis control boards exercise approval authority over all license transfers and ownership changes, creating regulatory risk in multi-state transactions. The Massachusetts Cannabis Control Commission requires 90-day advance notice of ownership changes exceeding 10% and conducts background investigations on all beneficial owners. The agency denied four license transfer applications in 2025 based on suitability concerns, demonstrating independent review authority that can block transactions. The Illinois Department of Financial and Professional Regulation maintains a competitive review process for license transfers in the state's limited-license market, requiring economic impact analysis and public comment periods. The agency imposed license divestiture requirements on two major MSO acquisitions in 2024-2025, establishing precedent for antitrust-style review despite cannabis remaining federally illegal. New York's Office of Cannabis Management prioritizes social equity in license transfer approvals, requiring acquiring operators to maintain existing equity partnerships and employee retention commitments. The agency's 2025 guidance established a rebuttable presumption against transfers that would give a single operator more than 15% state market share, creating consolidation limits absent in most state programs.

Legal and Regulatory Framework

Cannabis M&A transactions operate under state law exclusively, as federal prohibition under 21 U.S.C. § 812 precludes federal securities law protections and interstate commerce authority. The Controlled Substances Act classifies cannabis as a Schedule I substance, making cultivation, distribution, and possession federal felonies punishable by up to five years imprisonment under 21 U.S.C. § 841. This prohibition creates unique transaction structures and risks absent in other industries. The Cole Memorandum, issued by Deputy Attorney General James Cole in August 2013, established DOJ enforcement priorities that effectively permitted state-legal cannabis operations. The memo's January 2018 rescission by Attorney General Jeff Sessions created uncertainty, though subsequent DOJ policy maintained de facto non-enforcement in states with comprehensive regulatory programs. The Rohrabacher-Farr Amendment, renewed annually in congressional appropriations since 2014, prohibits DOJ from using funds to prevent states from implementing medical cannabis laws, providing limited federal enforcement protection. State cannabis laws govern all licensing, ownership, and operational requirements. Vertical integration mandates in limited-license states including New York, Ohio, and Pennsylvania require single entities to control cultivation, processing, and retail, forcing acquirers to purchase entire supply chains rather than individual assets. Residency requirements in 14 states restrict ownership to state residents, complicating multi-state operator expansion and requiring complex ownership structures. License transferability varies significantly across states. California permits free transfer of licenses subject to regulatory approval and background checks, creating liquid markets for license sales. Florida prohibits license transfers entirely, requiring acquirers to purchase the licensed entity's equity rather than assets. Massachusetts allows transfers but imposes priority review for social equity applicants, creating right-of-first-refusal dynamics that affect transaction timing and valuation. State approval timelines range from 30 days in Oklahoma to 180 days in New York, with multi-state transactions requiring sequential approvals that can extend closing timelines beyond 12 months. Material adverse change clauses in acquisition agreements allocate risk for regulatory denial or unexpected conditions, with most deals including termination rights if approvals are not obtained within 12-18 months. Section 280E of the Internal Revenue Code prohibits federal tax deductions for businesses trafficking in Schedule I or II controlled substances, limiting deductible expenses to cost of goods sold. This provision increases effective tax rates to 40-70% for cannabis operators and affects M&A valuation by reducing after-tax cash flows. The DEA's proposed rescheduling to Schedule III would eliminate 280E application, potentially increasing operator valuations by 30-50% and triggering renewed M&A activity. Securities law compliance requires Canadian exchange listings or over-the-counter markets, as Nasdaq and NYSE prohibit listing companies violating federal law. The Canadian Securities Exchange hosts 32 U.S. MSOs, applying Canadian disclosure requirements under National Instrument 51-102. Over-the-counter markets including OTCQX and OTCQB provide U.S. trading access but lack institutional investor participation and liquidity. This limited capital access forces all-stock transaction structures as acquirers cannot access traditional debt or equity financing.

State-by-State M&A Landscape

California

California's open-license market and free transferability create the industry's most active M&A environment, with 847 license transfers processed in 2025. The state's 1,234 licensed retailers and 817 cultivation operations operate in a highly competitive market with wholesale cannabis prices declining from $1,400 per pound in 2020 to $380 per pound in 2025. This oversupply drives distressed sales as undercapitalized operators exit. Glass House Brands acquired seven California cultivation facilities in 2024-2025 for combined consideration under $45 million, consolidating production to achieve scale economies. The state's Department of Cannabis Control approves transfers within 60 days absent background issues, creating relatively efficient transaction processes.

Florida

Florida's vertically integrated license structure and transfer prohibition create a market dominated by 22 licensed operators, with M&A occurring through equity purchases rather than asset sales. Trulieve operates 127 of the state's 647 dispensaries, achieving market dominance through aggressive retail expansion rather than acquisition. The state's medical program generated $2.1 billion in 2025 sales, with adult-use legalization on the November 2026 ballot potentially tripling market size. License scarcity drives valuations, with minority stakes in licensed operators trading at 10-15x revenue multiples despite profitability challenges. Ayr Wellness acquired Liberty Health Sciences for $290 million in 2021, gaining a vertically integrated Florida license and 31 dispensaries.

Illinois

Illinois operates a limited-license market with 21 cultivation centers and 110 dispensary licenses, creating consolidation pressure as operators pursue vertical integration. Cresco Labs, GTI, Verano, and PharmaCann control 58% of retail sales, with the state's 2025 adult-use revenue reaching $1.67 billion. The Department of Financial and Professional Regulation requires economic impact analysis for license transfers, with approval timelines averaging 120 days. The state's social equity program awarded 185 conditional retail licenses in 2021-2022, with many recipients partnering with MSOs for capital and operational support. GTI acquired 10 Illinois dispensary licenses from smaller operators in 2023-2025 for undisclosed consideration, densifying Chicago-area coverage.

Massachusetts

Massachusetts permits up to three retail licenses per operator, limiting consolidation and creating a fragmented market of 298 licensed retailers generating $1.52 billion in 2025 sales. The Cannabis Control Commission's 2022 transfer moratorium, lifted in 2024 with new competitive review guidelines, slowed M&A activity. Curaleaf operates the maximum three retail locations plus cultivation and processing facilities acquired through the Grassroots transaction. The state's economic empowerment priority review for social equity applicants creates transaction complexity, with several operators facing license transfer denials based on inadequate equity partnership terms. Cresco Labs divested four Massachusetts dispensaries to obtain Columbia Care merger approval, selling to Ascend Wellness for $42 million in 2023.

Michigan

Michigan's open-license market hosts 730 licensed retailers and 494 cultivation operations, with free license transferability creating active M&A markets. The state's 2025 adult-use sales reached $2.89 billion, making it the third-largest state market. Wholesale cannabis prices declined to $850 per pound in 2025 from $2,200 in 2021, driving consolidation as smaller operators achieve insufficient margins. Verano acquired four Michigan cultivation facilities and 12 dispensaries in 2024 for $78 million, establishing vertical integration. The Cannabis Regulatory Agency approves transfers within 45 days, among the industry's fastest timelines.

New Jersey

New Jersey's limited-license structure initially awarded 13 vertically integrated licenses, with adult-use legalization in 2022 triggering expansion to 34 cultivation licenses and 102 retail licenses through 2025. Curaleaf operates three cultivation facilities and 15 dispensaries, the state maximum, achieving 23% market share in a $1.34 billion market. The Cannabis Regulatory Commission requires diversity and equity plan approval for all license transfers, with 2024 guidance establishing minority ownership and employment targets. GTI acquired a New Jersey cultivation license and three dispensaries from a distressed operator for $52 million in 2025, gaining entry to the New York metro market.

New York

New York's Office of Cannabis Management awarded 463 conditional retail licenses prioritizing social equity applicants, creating a fragmented market as adult-use sales launched in 2023. The state's 10 registered organizations holding medical licenses face competition from equity licensees, many of whom lack capital for buildouts. Curaleaf and Acreage Holdings operate the maximum four dispensaries each under legacy medical licenses. The state's 15% market share cap for any single operator limits consolidation, with OCM requiring Cresco Labs to divest licenses as a Columbia Care merger condition. Transaction approval timelines average 180 days, among the industry's longest. PharmaCann acquired a New York cultivation license and four dispensary locations for $85 million in 2024, establishing vertical integration.

Ohio

Ohio operates a limited-license medical program with 52 dispensary licenses and 27 cultivation licenses, with adult-use legalization approved by voters in November 2023 and sales launching in 2024. Cresco Labs, Curaleaf, and Verano each operate multiple dispensaries acquired through competitive applications and secondary market purchases. The Division of Cannabis Control requires 90-day approval timelines for license transfers, with background investigations on all beneficial owners. Adult-use market launch is projected to generate $1.8 billion in annual sales by 2026, driving acquisition interest. Ayr Wellness acquired three Ohio dispensary licenses from a regional operator for $28 million in 2025.

Pennsylvania

Pennsylvania's medical program operates with 50 vertically integrated permits each authorizing up to nine dispensary locations, creating a structured market generating $1.96 billion in 2025 sales. Curaleaf, Cresco Labs, GTI, and Trulieve each operate the maximum nine dispensaries under acquired permits. The Department of Health requires diversity plan approval and maintains a 120-day transfer review timeline. Adult-use legalization remains under legislative consideration, with passage potentially doubling market size. Jushi Holdings acquired a Pennsylvania permit and six operating dispensaries for $110 million in 2023, establishing a vertically integrated position.

Market and Business Implications

Cannabis M&A transaction structures prioritize all-stock consideration to preserve cash, with 78% of deals by value using equity rather than cash in 2024-2025. MSOs maintain limited cash reserves due to 280E tax burdens, high-interest debt, and capital expenditure requirements for facility buildouts. Stock-based transactions allow acquirers to preserve liquidity while offering sellers equity participation in combined entity upside. This structure creates alignment but introduces execution risk, as target shareholders bear integration and operational risks post-closing. Earnout provisions appear in 64% of cannabis M&A transactions, according to Viridian Capital analysis, compared to 25% in traditional M&A markets. These contingent payments bridge valuation gaps between buyer and seller expectations, with consideration tied to revenue, EBITDA, or license approval milestones over 12-36 month periods. Earnouts shift risk to sellers while reducing upfront capital requirements for buyers. Disputes over earnout achievement drive post-closing litigation, with several high-profile cases including MedMen's contested earnout payments to acquired operators. Valuation multiples compressed from 8-12x forward revenue in 2020-2021 to 2-4x forward revenue in 2024-2026 as capital markets repriced growth expectations and profitability timelines. EBITDA multiples range from 6-10x for profitable operators with diversified state portfolios, while unprofitable single-state operators trade at 1-2x revenue or distressed asset values. License scarcity in limited-license states commands premium valuations, with vertically integrated permits in New York, Pennsylvania, and Illinois valued at $50-150 million depending on operational status and market position. Wholesale pricing dynamics affect vertical integration acquisition strategies. States with oversupply including California, Michigan, and Oklahoma see wholesale cannabis prices below $500 per pound, making cultivation operations marginally profitable and reducing vertical integration value. Conversely, supply-constrained markets including New York, New Jersey, and Pennsylvania maintain wholesale prices above $2,000 per pound, creating strong margins for vertically integrated operators and driving acquisition interest in cultivation licenses. Debt financing constraints limit transaction size and structure options. Cannabis operators cannot access traditional bank financing due to federal prohibition, relying instead on high-interest credit facilities from specialized lenders at 12-18% interest rates. This expensive capital limits acquisition financing availability, forcing operators to use equity or seller financing. Several major MSOs carry debt-to-EBITDA ratios exceeding 4x, constraining additional borrowing capacity and limiting M&A activity until debt reduction occurs. Tax implications under 280E affect transaction economics significantly. Buyers cannot deduct goodwill amortization or most acquisition-related expenses, reducing tax benefits compared to traditional M&A. Asset purchases allow buyers to step up basis in tangible assets including inventory and equipment, creating some tax efficiency. Stock purchases provide no step-up but avoid transfer taxes and simplify regulatory approvals. The proposed Schedule III rescheduling would eliminate 280E application, potentially increasing after-tax cash flows by 30-50% and driving valuation increases that enable renewed M&A activity.

What Industry Participants Say

Boris Jordan, Executive Chairman of Curaleaf Holdings, stated in the company's Q4 2025 earnings call that consolidation will accelerate as undercapitalized operators face margin compression and seek exits. According to Jordan, Curaleaf maintains a disciplined acquisition approach focused on vertically integrated assets in limited-license states where regulatory barriers create sustainable competitive advantages. The company's acquisition pipeline includes opportunities in New York, Pennsylvania, and New Jersey, where adult-use market expansion creates growth potential for scaled operators. Ben Kovler, CEO of Green Thumb Industries, said during a February 2026 investor presentation that GTI prioritizes organic growth over M&A, believing new market entry through competitive license applications provides better returns than acquiring existing operations at premium valuations. According to Kovler, the company evaluates 30-40 acquisition opportunities annually but completes only selective tuck-in transactions that add retail density in existing markets or provide specific capability gaps. Emily Paxhia, co-founder of Poseidon Investment Management, stated in a March 2026 industry conference that private equity investors view the current environment as favorable for acquisitions, with distressed operators seeking liquidity at reasonable valuations. According to Paxhia, successful M&A strategies focus on operational improvement and cost synergies rather than revenue growth assumptions, reflecting lessons from the 2020-2021 period when acquirers overpaid based on optimistic federal reform timelines. Andrew Kline, partner at Perkins Coie and cannabis regulatory attorney, said in Congressional testimony in May 2025 that state-by-state regulatory approval processes create significant transaction risk and cost. According to Kline, multi-state deals require 8-12 months for regulatory approvals, with legal and consulting costs ranging from $500,000 to $2 million depending on transaction complexity. He noted that regulatory uncertainty around approval standards and timelines discourages some transactions entirely. Bethany Gomez, Managing Director of Brightfield Group, stated in the firm's 2026 M&A outlook report that transaction volume will increase 35-40% in 2026 compared to 2025, driven by federal rescheduling momentum and improved operator profitability. According to Gomez, strategic buyers focus on vertical integration in limited-license states, while financial buyers target profitable single-state operators with strong management teams. She projects total transaction value reaching $2.8-3.2 billion in 2026.

What Comes Next

The DEA's proposed rescheduling of cannabis to Schedule III under 21 U.S.C. § 812 represents the most significant near-term catalyst for M&A activity, with a final rule expected in late 2026 or early 2027. The agency published a notice of proposed rulemaking in May 2024 following HHS recommendation, with public comment periods and administrative law judge hearings extending the process. Schedule III classification would eliminate 280E tax penalties, potentially increasing MSO after-tax cash flows by 30-50% and driving valuation increases that enable stock-based acquisitions. Operators are positioning for this catalyst through debt reduction and operational efficiency improvements to maximize acquisition capacity when rescheduling occurs. State adult-use legalization votes in Ohio, Pennsylvania, and Florida through 2024-2027 will create market expansion opportunities driving M&A activity. Florida's November 2026 adult-use ballot initiative, if approved, would create a $5-7 billion market and trigger consolidation among the state's 22 licensed operators. Pennsylvania's legislative consideration of adult-use legalization could double the state's $2 billion medical market, making vertically integrated permits more valuable and attracting acquisition interest. Distressed operator exits will continue as margin compression affects undercapitalized companies. Several mid-sized MSOs including Jushi Holdings, Ayr Wellness, and TerrAscend face debt maturities in 2026-2027 with limited refinancing options at current valuations. These operators may pursue strategic sales or asset divestitures to reduce leverage, creating acquisition opportunities for larger MSOs with stronger balance sheets. Analysts project 15-20 significant distressed transactions in 2026-2027 as operators face refinancing challenges. Canadian licensed producer re-entry into U.S. M&A markets remains possible if federal reform advances. Canopy Growth, Tilray Brands, and Cronos Group maintain U.S. acquisition strategies contingent on federal legalization or rescheduling. These companies possess stronger balance sheets and public market access compared to U.S. MSOs, potentially enabling transformative transactions if federal barriers are removed. Canopy's restructured Acreage Holdings agreement and Tilray's acquisition of convertible notes in several U.S. operators position these companies for rapid U.S. market entry. Vertical integration will drive acquisition strategies in limited-license states as operators pursue supply chain control. New York, New Jersey, and Pennsylvania operators lacking cultivation capacity will target license acquisitions to achieve vertical integration and capture wholesale margins. Conversely, cultivation-focused operators in oversupplied markets including California and Michigan may divest production assets to focus on branded product distribution and retail. Technology and brand acquisitions will increase as operators pursue differentiation beyond commodity cannabis. Several MSOs including Curaleaf and Cresco Labs acquired branded product lines including Select Oil and Mindy's Edibles to build consumer loyalty and premium pricing power. Extraction technology, genetics libraries, and retail technology platforms represent acquisition targets as operators standardize operations across multi-state footprints.

Further Reading

• Viridian Capital Advisors Cannabis Deal Tracker — Quarterly M&A transaction database and analysis: https://www.viridianca.com/deal-tracker
• U.S. Drug Enforcement Administration, Notice of Proposed Rulemaking on Cannabis Rescheduling (May 2024) — Federal Register Vol. 89, No. 97: https://www.federalregister.gov/documents/2024/05/21/2024-10633/schedules-of-controlled-substances-rescheduling-of-marijuana
• Controlled Substances Act, 21 U.S.C. § 812 — Federal drug scheduling statute: https://www.gov